

POSTER PRESENTATION

Open Access

Efficacy and tolerability of darunavir/r 600/100 mg bid in treatment-experienced patients: 48-week data from a German outpatient cohort

J van Lunzen^{1*}, D Gorriahn², T Wünsche³, S Dupke⁴, P Gute⁵, CK Schewe⁶, B Ranneberg⁷

From Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010

Background

Darunavir/Ritonavir (DRV/r) dosed 600/100 mg bid has shown good efficacy and tolerability in treatment-experienced patients in clinical trials (POWER, TITAN). To assess whether these results can be transferred to clinical practice and a more diverse patient population this prospective non-interventional Janssen-sponsored cohort study was established.

Methods

Between August 2007 and March 2009, 340 HIV-1 infected antiretroviral-experienced patients from 62 German centers enrolled in this non-interventional cohort. All patients received DRV/r 600/100 mg bid as part of their HAART. Virological and immunological response was monitored every 3 months. Patients were followed for up to 48 weeks.

Results

296/340 (87%) patients were male with a mean age of 47 years (SD 9.9); median time since HIV diagnosis was 12 years. At baseline, mean viral load (VL) was 4.7 log₁₀ copies/mL (SD 5.44) with a mean CD4 count of 392 cells/mm³ (SD 251); 213 (63%) patients started therapy with CD4 < 200 cells/mm³. Patients had been pretreated with NRTIs (94%), PIs (88%), NNRTIs (63%), FI (11%), INI (5%) and/or CCR5 (3%). No data is available for 17 patients. At baseline, only 138 patients received DRV/r in combination with 2 NRTIs; the majority (202/340) of patients received DRV/r in different combinations based on the individual pretreatment situation. Of note, 116 patients received a combination containing DRV/r, RAL

+ other antiretrovirals. ETR and DRV/r plus other ARVs were used in 23 patients. 51 patients received an NRTI-sparing regimen. At the time of this analysis, 32 patients had discontinued prematurely and 251/340 patients had reached week 48. VL and CD4 measurements at week 48 are available for 186 patients, 80.6 % patients achieved a VL < 50 copies/ml (VL < 400 copies/ml: 94.6 %), mean CD4 count in these patients (n=185) increased from 402 at baseline to 476 cells/mm³ (SD: 262; p <0.001). 10 patients (2.9%) discontinued DRV/r due to adverse events. Virological failure (VL >50 copies/mL at 2 visits) was documented in 10 patients (2.9%). 3 patients were genotyped; primary PI mutations were detected in all 3 patients, DRV-RAMs in none of them.

Conclusions

Overall, Darunavir/r, dosed at 600/100 mg bid in combination with other antiretrovirals, showed good efficacy and safety in treatment-experienced patients in clinical practice.

Author details

¹Universitätsklinikum Eppendorf, Ambulanzzentrum des UKE, Bereich Infektiologie, Hamburg, Germany. ²Private Practice, München, Germany. ³Private Practice, Berlin, Germany. ⁴Praxis Driesener Strasse, Berlin, Germany. ⁵Infektiologikum Frankfurt, Frankfurt, Germany. ⁶ICH Hamburg, Hamburg, Germany. ⁷Janssen, Johnson&Johnson-Platz 1, Neuss, Germany.

Published: 8 November 2010

doi:10.1186/1758-2652-13-S4-P28

Cite this article as: van Lunzen et al.: Efficacy and tolerability of darunavir/r 600/100 mg bid in treatment-experienced patients: 48-week data from a German outpatient cohort. *Journal of the International AIDS Society* 2010 **13**(Suppl 4):P28.

¹Universitätsklinikum Eppendorf, Ambulanzzentrum des UKE, Bereich Infektiologie, Hamburg, Germany

Full list of author information is available at the end of the article